{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"A priori p-value significance threshold: 1-sided ≤0.10","statisticalMethod":"Regression, Logistic"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"41"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"102"},{"groupId":"OG001","value":"98"}],"units":"Participants"}],"description":"ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis (RA). An ACR20 Responder is a participant who had ≥20% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥20% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (assessment of participant's physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time point are treated as non-responders. Percentage of participants achieving ACR20 response = (number of ACR20 responders) / (number of participants analyzed) \\* 100.","groups":[{"description":"4 or 8 mg LY3009104 administered orally QD for 12 weeks in Part A.\n\nMTX was administered orally as background therapy.","id":"OG000","title":"4 or 8 mg LY3009104"},{"description":"Placebo administered orally QD for 12 weeks in Part A.\n\nMTX was administered orally as background therapy.","id":"OG001","title":"Placebo"}],"paramType":"NUMBER","populationDescription":"All randomized participants who received placebo, 4 mg or 8 mg LY3009104 in Part A. Participants who had missing components of the ACR20 index at Week 12 had these components imputed by last observation carried forward (LOCF).","reportingStatus":"POSTED","timeFrame":"Baseline through Week 12","title":"Percentage of Participants in the 4 mg and 8 mg Dose Groups Who Achieved an American College of Rheumatology 20 (ACR20) Responder Index Response Baseline Through Week 12","type":"PRIMARY","unitOfMeasure":"percentage of participants"}